Determination of Serum Antibody to Bordetella pertussis Adenylate Cyclase Toxin in Vaccinated and Unvaccinated Children and in Children and Adults with Pertussis

Clinical Infectious Diseases

Volumn 38, Issue 4, 2004, Pages 502-507

  Cherry, James D ^a   Xing, Dorothy X L ^b   Newland, Penny ^b   Patel, Kashmira ^c   Heininger, Ulrich ^d   Corbel, Michael J ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^c UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

^d UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; ANTIBODY; DIPHTHERIA PERTUSSIS TETANUS VACCINE;

ADOLESCENT; ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; BORDETELLA PERTUSSIS; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MAJOR CLINICAL STUDY; PERTUSSIS; PRIORITY JOURNAL; WESTERN BLOTTING;

ADENYLATE CYCLASE TOXIN; ADULT; ANTIBODIES; BORDETELLA INFECTIONS; BORDETELLA PERTUSSIS; CHILD; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOBLOTTING; WHOOPING COUGH;

EID: 1342301472     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/381204     Document Type: Article

References (24)

1. Cherry JD, Heininger U. Pertussis and other Bordetella infections. In: Cherry JD, Feigin RD, eds. Textbook of pediatric infectious diseases. 5th ed. Philadelphia: Saunders, 2003:1588-608.
2. Kerr JR, Matthews RC. Bordetella pertussis infection: pathogenesis, diagnosis, management, and the role of protective immunity. Eur J Clin Microbiol Infect Dis 2000; 19:77-88.
3. Westrop GD, Hormozi EK, Da Costa NA, Parton R, Coote JG. Bordetella pertussis adenylate cyclase toxin: proCyaA and CyaC proteins synthesised separately in Escherichia coli produce active toxin in vitro. Gene 1996; 180:91-9.
4. Betsou F, Sebo P, Guiso N. CyaC-mediated activation is important not only for toxic but also for protective activities of Bordetella pertussis adenylate cyclase-hemolysin. Infect Immun 1993; 61:3583-9.
5. Confer DL, Eaton JW. Bordetella adenylate cyclase: host toxicity and diagnostic utility. Dev Biol Stand 1985; 61:3-10.
6. Arciniega JL, Hewlett EL, Johnson FD, et al. Human serologic response to envelope-associated proteins and adenylate cyclase toxin of Bordetella pertussis. J Infect Dis 1991; 163:135-42.
7. Farfel Z, Könen S, Wiertz E, Kalpmuts R, Addy PA-K, Hanski E. Antibodies to Bordetella pertussis adenylate cyclase are produced in man during pertussis infection and after vaccination. J Med Microbiol 1990; 32:173-7.
8. Stehr K, Cherry JD, Heininger U, et al. A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine. Pediatrics 1998; 101:1-11.
9. Gustafsson L, Hallander HO, Olin P, Reizenstein E, Storsaeter J. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med 1996; 334:349-55.
10. Heininger U, Klich K, Stehr K, Cherry JD. Clinical findings in Bordetella pertussis infections: results of a prospective multicenter surveillance study. Pediatrics 1997; 100:E10.
11. Heininger U, Cherry JD, Stehr K. Serologic response and antibody-titer decay in adults with pertussis. Clin Infect Dis 2004; 38:591-4 (in this issue).
12. Olin P, Rasmussen F, Gustafsson L, Hallander HO, Heijbel H. Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines. Lancet 1997; 350:1569-77.
13. Greco D, Salmaso S, Mastrantonio P, et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group. N Engl J Med 1996; 334:341-8.
14. Cherry JD. Epidemiological, clinical, and laboratory aspects of pertussis in adults. Clin Infect Dis 1999; 28(Suppl 2):S112-7.
15. Deen JL, Mink CA, Cherry JD, et al. Household contact study of Bordetella pertussis infections. Clin Infect Dis 1995; 21:1211-9.
16. Blennow M, Granström M, Jäätmaa E, Olin P. Primary immunization of infants with an acellular pertussis vaccine in a double-blind randomized clinical trial. Pediatrics 1988; 82:293-9.
17. Cotter PA, Miller JF. Bordetella. In: Groisman EA, ed. Principles of bacterial pathogenesis. San Diego: Academic, 2001:636-7.
18. Arciniega JL, Hewlett EL, Edwards KM, Burns DL. Antibodies to Bordetella pertussis adenylate cyclase toxin in neonatal and maternal sera. FEMS Immunol Med Microbiol 1993; 6:325-30.
19. Ehrmann IE, Gray MC, Gordon VM, Gray LS, Hewlett EL. Hemolytic activity of adenylate cyclase toxin from Bordetella pertussis. FEBS Lett 1991; 278:79-83.
20. Stryer L. Cyclic AMP, a second messenger in the action of many hormones, is formed by adenylate cyclase. In: Biochemistry. 4th ed. New York: WH Freeman, 1995:340-3.
21. Goyard S, Orlando C, Sabatier JM, et al. Identification of a common domain in calmodulin-activated eukaryotic and bacterial adenylate cyclases. Biochemistry 1989; 28:1964-7.
22. Janeway CAJ, Travers P, Walport M, Capra JD. Immunological memory. In: Austin P, Lawrence E, eds. Immunobiology: the immune system in health and disease. 4th ed. New York: Elsevier, 1999:402-13.
23. Hodder SL, Cherry JD, Mortimer EA Jr, Ford AB, Gornbein JA, Papp KL. Antibody responses to Bordetella pertussis antigens and clinical correlations in elderly community residents. Clin Infect Dis 2000; 31:7-14.
24. Vincent JM, Cherry JD, Nauschuetz WF, et al. Prolonged afebrile non-productive cough illnesses in American soldiers in Korea: a serologic search for causation. Clin Infect Dis 2000; 30:534-9.